Molecular docking and pharmacophore model studies of Rho kinase inhibitors

Molecular Simulation

Volumn 37, Issue 6, 2011, Pages 488-494

  Wang, Dong Hua ^a   Qu, Wan Lu ^a   Shi, Liu Qing ^a   Wei, Jing ^a  

^a TIANJIN UNIVERSITY   (China)

Author keywords

computer aided drug design; molecular docking; pharmacophore model; Rho kinase; Rho kinase inhibitor

Indexed keywords

COMPUTER-AIDED DRUG DESIGN; MOLECULAR DOCKING; PHARMACOPHORE MODELS; RHO KINASE; RHO-KINASE INHIBITORS;

BINDING ENERGY; DOCKING; ENZYMES; HYDROGEN; HYDROGEN BONDS; MOLECULAR MODELING; PHARMACODYNAMICS; ROCKS;

THREE DIMENSIONAL;

EID: 79957585276     PISSN: 08927022     EISSN: 10290435     Source Type: Journal    
DOI: 10.1080/08927022.2011.554548     Document Type: Article

References (74)

1. J. Chang, M. Xie, V.R. Shah, M.D. Schneider, M.L. Entman, L. Wei, and R.J. Schwartz, Activation of Rho-associated coiled-coil protein kinase 1 (ROCK-1) by caspase-3 cleavage plays an essential role in cardiac myocyte apoptosis, Proc. Natl Acad. Sci. USA 103 (2006), pp. 14495-14500. (Pubitemid 44484778)
2. R.D.P. Del, S. Miyamoto, and J.H. Brown, RhoA/Rho kinase upregulate Bax to activate a mitochondrial death pathway and induce cardiomyocyte apoptosis, J. Biol. Chem. 282 (2007), pp. 8069-8078. (Pubitemid 47093605)
3. Y. Fukata, M. Amano, and K. Kaibuchi, Rho-Rho-kinase pathway in smooth muscle contraction and cytoskeletal reorganization of nonmuscle cells, Trends Pharmacol. Sci. 22 (2001), pp. 32-39. (Pubitemid 32126284)
4. S. Micuda, D. Rosel, A. Ryska, and J. Brabek, ROCK inhibitors as emerging therapeutic candidates for sarcomas, Curr. Cancer Drug Tar. 10 (2010), pp. 127-134.
5. M. Tamura, H. Nakao, H. Yoshizaki, M. Shiratsuchi, H. Shigyo, H. Yamada, T. Ozawa, J. Totsuka, and H. Hidaka, Development of specific Rho-kinase inhibitors and their clinical application, Biochim. Biophys. Acta 1754 (2005), pp. 245-252. (Pubitemid 41797705)
6. W.G. Duan, S.T. Yuan, H. Liao, M. Yan, and L.Y. Zhang, Advances in the study of Rho kinase and its inhibitors, Acta Pharm. Sin. 42 (2007), pp. 1013-1022.
7. Y. Sasakia, M. Suzukib, and H. Hidaka, The novel and specific Rhokinase inhibitor (S)-(+)-2-methyl-1- [(4-methyl-5-isoquinoline)sulfonyl]- homopiperazine as a probing molecule for Rho-kinaseinvolved pathway, Pharmacol. Ther. 93 (2002), pp. 225-232. (Pubitemid 34615563)
8. T. Bosanac, E.R. Hickey, J. Ginn, M. Kashem, S. Kerr, S. Kugler, X. Li, A. Olague, S. Schlyer, and E.R.R. Young, Substituted 2Hisoquinolin- 1-ones as potent Rho-kinase inhibitors: Part 3, aryl substituted pyrrolidines, Bioorg. Med. Chem. Lett. 20 (2010), pp. 3746-3749.
9. H. Lin, D.S. Yamashita, J. Zeng, R. Xie, W. Wang, S. Nidarmarthy, J.I. Luengo, N. Rhodes, V. Knick, A. Choudhry, Z. Lai, E.A. Minthorn, S.L. Strum, E.R. Wood, P.A. Elkins, N.O. Concha, and D.A. Heerding, 2,3,5-Trisubstituted pyridines as selective AKT inhibitors - Part I: Substitution at 2-position of the core pyridine for ROCK1 selectivity, Bioorg. Med. Chem. Lett. 20 (2010), pp. 673-678.
10. R.L. Davis, M. Kahraman, T.J. Prins, Y. Beaver, T.G. Cook, J. Cramp, C.S. Cayanan, E.M.M. Gardiner, M.A. McLaughlin, A.F. Clark, M.R. Hellberg, A.K. Shiau, S.A. Noble, and A.J. Borchardt, Benzothiophene containing Rho kinase inhibitors: Efficacy in an animal model of glaucoma, Bioorg. Med. Chem. Lett. 20 (2010), pp. 3361-3366.
11. F. Wu, F.H. Buttner, R. Chen, E. Hickey, S. Jakes, P. Kaplita, M.A. Kashem, S. Kerr, S. Kugle, Z. Paw, A. Prokopowicz, C.K. Shih, R. Snow, E. Young, and C.L. Cywin, Substituted 2H-isoquinolin-1-one as potent Rho-kinase inhibitors. Part 1: Hit-to-lead account, Bioorg. Med. Chem. Lett. 20 (2010), pp. 3235-3239.
12. K.C. Chou, Review: Structural bioinformatics and its impact to biomedical science, Curr. Med. Chem. 11 (2004), pp. 2105-2134.
13. K.C. Chou, Modelling extracellular domains of GABA-A receptors: Subtypes 1, 2, 3, and 5, Biochem. Biophys. Res. Commun. 316 (2004), pp. 636-642.
14. K.C. Chou, Molecular therapeutic target for type-2 diabetes, J. Proteome Res. 3 (2004), pp. 1284-1288.
15. T. Huang, X.H. Shi, P. Wang, Z. He, K.Y. Feng, L. Hu, X. Kong, Y.X. Li, Y.D. Cai, and K.C. Chou, Analysis and prediction of the metabolic stability of proteins based on their sequential features, subcellular locations and interaction networks, PLoS ONE 5 (2010), p. e10972.
16. K.C. Chou, D.Q. Wei, and W.Z. Zhong, Binding mechanism of coronavirus main proteinase with ligands and its implication to drug design against SARS, Biochem. Biophys. Res. Commun. 308 (2003), pp. 148-151.
17. Z.S. He, J. Zhang, X.H. Shi, L.L. Hu, X.G. Kong, Y.D. Cai, and K.C. Chou, Predicting drug-target interaction networks based on functional groups and biological features, PLoS ONE 5 (2010), p. e9603.
18. K.C. Chou, D.Q. Wei, Q.S. Du, S. Sirois, and W.Z. Zhong, Review: Progress in computational approach to drug development against SARS, Curr. Med. Chem. 13 (2006), pp. 3263-3270. (Pubitemid 44669774)
19. K.C. Chou and H.B. Shen, Cell-PLoc: A package of web servers for predicting subcellular localization of proteins in various organisms, Nat. Protocols 3 (2008), pp. 153-162.
20. K.C. Chou and H.B. Shen, Review: Recent progresses in protein subcellular location prediction, Anal. Biochem. 370 (2007), pp. 1-16.
21. K.C. Chou and H.B. Shen, A new method for predicting the subcellular localization of eukaryotic proteins with both single and multiple sites: Euk-mPLoc 2.0, PLoS ONE 5 (2010), p. e9931.
22. K.C. Chou and H.B. Shen, Cell-PLoc 2.0: An improved package of web-servers for predicting subcellular localization of proteins in various organisms, Nat. Sci. 2 (2010), pp. 1090-1103.
23. X. Xiao, P. Wang, and K.C. Chou, GPCR-CA: A cellular automaton image approach for predicting G-protein-coupled receptor functional classes, J. Comput. Chem. 30 (2009), pp. 1414-1423.
24. K.C. Chou and H.B. Shen, ProtIdent: A web server for identifying proteases and their types by fusing functional domain and sequential evolution information, Biochem. Biophys. Res. Commun. 376 (2008), pp. 321-325.
25. K.C. Chou, A vectorized sequence-coupling model for predicting HIV protease cleavage sites in proteins, J. Biol. Chem. 268 (1993), pp. 16938-16948.
26. K.C. Chou, Review: Prediction of HIV protease cleavage sites in proteins, Anal. Biochem. 233 (1996), pp. 1-14.
27. L. Chen, K.Y. Feng, Y.D. Cai, K.C. Chou, and H.P. Li, Predicting the network of substrate-enzyme-product triads by combining compound similarity and functional domain composition, BMC Bioinform. 11 (2010), p. 293.
28. K.C. Chou and H.B. Shen, Signal-CF: A subsite-coupled and window-fusing approach for predicting signal peptides, Biochem. Biophys. Res. Commun. 357 (2007), pp. 633-640.
29. H. Yamaguchi, M. Kasa, M. Amano, K. Kaibuchi, and T. Hakoshima, Molecular mechanism for the regulation of Rho-kinase by dimerization and its inhibition by Fasudil, Structure 14 (2006), pp. 589-600. (Pubitemid 43363491)
30. H. Yamaguchi, Y. Miwa, M. Kasa, K. Kitano, M. Amano, K. Kaibuchi, and T. Hakoshima, Structural basis for induced-fit binding of Rho-kinase to the inhibitor Y-27632, J. Biochem. 140 (2006), pp. 305-311. (Pubitemid 44703147)
31. R. Dvorsky, L. Blumenstein, I.R. Vetter, and M.R. Ahmadian, Structural insights into the interaction of ROCKI with the switch regions of RhoA, J. Biol. Chem. 279 (2004), pp. 7098-7104. (Pubitemid 38248856)
32. S.F. Sousa, P.A. Fernandes, and M.J. Ramos, Protein-ligand docking: Current status and future challenges, Proteins 65 (2006), pp. 15-26. (Pubitemid 44320611)
33. D.Q. Wei, R. Zhang, Q.S. Du, W.N. Gao, Y. Li, H. Gao, S.Q. Wang, X. Zhang, A.X. Li, S. Sirois, and K.C. Chou, Anti-SARS drug screening by molecular docking, Amino Acids 31 (2006), pp. 73-80. (Pubitemid 44086400)
34. Q.S. Du, S.Q. Wang, R.B. Huang, and K.C. Chou, Computational 3D structures of drug-targeting proteins in the 2009-H1N1 influenza A virus, Chem. Phys. Lett. 485 (2010), pp. 191-195.
35. Q.S. Du, R.B. Huang, C.H. Wang, X.M. Li, and K.C. Chou, Energetic analysis of the two controversial drug binding sites of the M2 proton channel in influenza A virus, J. Theor. Biol. 259 (2009), pp. 159-164.
36. C. Hetenyi and D. van der Spoel, Efficient docking of peptides to proteins without prior knowledge of the binding site, Protein Sci. 11 (2002), pp. 1729-1737. (Pubitemid 34663553)
37. J. Wei, H. Li, W.L. Qu, and Q.Z. Gao, Molecular docking study of A3 adenosine receptor antagonists and pharmacophore-based drug design, Neurochem. Int. 55 (2009), pp. 637-642.
38. N.A. Caballero, F.J. Melendez, A. Nino, and C. Munoz-Caro, Molecular docking study of the binding of aminopyridines within the K + channel, J. Mol. Model. 13 (2007), pp. 579-586. (Pubitemid 46681656)
39. H.A. Jung, S.H. Oh, and J.S. Choi, Molecular docking studies of phlorotannins from Eisenia bicyclis with BACE1 inhibitory activity, Bioorg. Med. Chem. Lett. 20 (2010), pp. 3211-3215.
40. A. Takami,M. Iwakubo, and Y. Okada, Design and synthesis of Rho kinase inhibitors (I), Bioorg. Med. Chem. 12 (2004), pp. 2115-2137. (Pubitemid 38471702)
41. A. Takami,M. Iwakubo, and Y. Okada, Design and synthesis of Rho kinase inhibitors (II), Bioorg. Med. Chem. 15 (2007), pp. 350-364. (Pubitemid 44738570)
42. A. Takami,M. Iwakubo, and Y. Okada, Design and synthesis of Rho kinase inhibitors (III), Bioorg. Med. Chem. 15 (2007), pp. 1022-1033. (Pubitemid 44880705)
43. G.M. Morris, D.S. Goodsell, R.S. Halliday, R. Huey, W.E. Hart, R.K. Belew, and A.J. Olson, Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function, J. Comput. Chem. 19 (1998), pp. 1639-1662. (Pubitemid 128590223)
44. J. Wei, S.Q. Wang, S.F. Gao, X.D. Dai, and Q.Z. Gao, 3Dpharmacophore models for selective A2A and A2B adenosine receptor antagonists, J. Chem. Inf. Model. 47 (2007), pp. 613-625. (Pubitemid 46615962)
45. M. Chopra, R. Gupta, S. Gupta, and D. Saluja, Molecular modeling study on chemically diverse series of cyclooxygenase-2 selective inhibitors: Generation of predictive pharmacophore model using Catalyst, J. Mol. Model. 14 (2008), pp. 1087-1099.
46. J. Wei, Y.X. Liu, and S.Q. Wang, 3D pharmacophore models for thromboxane A2 receptor antagonists, J. Mol. Model. 15 (2009), pp. 1185-1191.
47. Y.D. Ye, Q.H. Liao, J. Wei, and Q.Z. Gao, 3D-QSAR study of corticotropin-releasing factor 1 antagonists and pharmacophorebased drug design, Neurochem. Int. 56 (2010), pp. 107-117.
48. K.C. Chou, K.D. Watenpaugh, and R.L. Heinrikson, A model of the complex between cyclin-dependent kinase 5 (Cdk5) and the activation domain of neuronal Cdk5 activator, Biochem. Biophys. Res. Commun. 259 (1999), pp. 420-428. (Pubitemid 29281247)
49. J. Zhang, C.H. Luan, K.C. Chou, and G.V.W. Johnson, Identification of the N-terminal functional domains of Cdk5 by molecular truncation and computer modeling, Proteins 48 (2002), pp. 447-453. (Pubitemid 34810411)
50. K.C. Chou, Insights from modelling the 3D structure of the extracellular domain of alpha7 nicotinic acetylcholine receptor, Biochem. Biophys. Res. Commun. 319 (2004), pp. 433-438.
51. D.Q. Wei, Q.S. Du, H. Sun, and K.C. Chou, Insights from modeling the 3D structure of H5N1 influenza virus neuraminidase and its binding interactions with ligands, Biochem. Biophys. Res. Commun. 344 (2006), pp. 1048-1055.
52. S.Q. Wang, Q.S. Du, and K.C. Chou, Study of drug resistance of chicken influenza A virus (H5N1) from homology-modeled 3D structures of neuraminidases, Biochem. Biophys. Res. Commun. 354 (2007), pp. 634-640.
53. Q.S. Du, H. Sun, and K.C. Chou, Inhibitor design for SARS coronavirus main protease based on 'distorted key theory', Med. Chem. 3 (2007), pp. 1-6. (Pubitemid 46062335)
54. M.R. Housaindokht, M.R. Bozorgmehr, and M. Bahrololoom, Analysis of ligand binding to proteins using molecular dynamics simulations, J. Theor. Biol. 254 (2008), pp. 294-300.
55. J.F. Wang, D.Q. Wei, L. Li, S.Y. Zheng, Y.X. Li, and K.C. Chou, 3D structure modeling of cytochrome P450 2C19 and its implication for personalized drug design, Biochem. Biophys. Res. Commun. 355 (2007), pp. 513-519. (Pubitemid 46282658)
56. R.B. Huang, Q.S. Du, C.H. Wang, and K.C. Chou, An in-depth analysis of the biological functional studies based on the NMR M2 channel structure of influenza A virus, Biochem. Biophys. Res. Commun. 377 (2008), pp. 1243-1247.
57. J.R. Schnell and J.J. Chou, Structure and mechanism of the M2 proton channel of influenza A virus, Nature 451 (2008), pp. 591-595. (Pubitemid 351186272)
58. K.C. Chou, D. Jones, and R.L. Heinrikson, Prediction of the tertiary structure and substrate binding site of caspase-8, FEBS Lett. 419 (1997), pp. 49-54. (Pubitemid 28011215)
59. J.F. Wang, D.Q. Wei, C. Chen, Y. Li, and K.C. Chou, Molecular modeling of two CYP2C19 SNPs and its implications for personalized drug design, Protein Peptide Lett. 15 (2008), pp. 27-32. (Pubitemid 351206472)
60. H. Wei, C.H. Wang, Q.S. Du, J. Meng, and K.C. Chou, Investigation into adamantane-based M2 inhibitors with FB-QSAR, Med. Chem. 5 (2009), pp. 305-317.
61. L. Li, D.Q. Wei, J.F. Wang, and K.C. Chou, Computational studies of the binding mechanism of calmodulin with chrysin, Biochem. Biophys. Res. Commun. 358 (2007), pp. 1102-1107. (Pubitemid 46829002)
62. J.F. Wang, D.Q. Wei, Y. Lin, Y.H. Wang, H.L. Du, Y.X. Li, and K.C. Chou, Insights from modeling the 3D structure of NAD(P)Hdependent D-xylose reductase of Pichia stipitis and its binding interactions with NAD and NADP, Biochem. Biophys. Res. Commun. 359 (2007), pp. 323-329. (Pubitemid 46887686)
63. R.X. Gu, H. Gu, Z.Y. Xie, J.F. Wang, H.R. Arias, D.Q. Wei, and K.C. Chou, Possible drug candidates for Alzheimer's disease deduced from studying their binding interactions with alpha7 nicotinic acetylcholine receptor, Med. Chem. 5 (2009), pp. 250-262.
64. K. Gong, L. Li, J.F. Wang, F. Cheng, D.Q. Wei, and K.C. Chou, Binding mechanism of H5N1 influenza virus neuraminidase with ligands and its implication for drug design, Med. Chem. 5 (2009), pp. 242-249.
65. J.F. Wang, J.Y. Yan, D.Q. Wei, and K.C. Chou, Binding of CYP2C9 with diverse drugs and its implications for metabolic mechanism, Med. Chem. 5 (2009), pp. 263-270.
66. K.C. Chou, Coupling interaction between thromboxane A2 receptor and alpha-13 subunit of guanine nucleotide-binding protein, J. Proteome. Res. 4 (2005), pp. 1681-1686.
67. G.P. Zhou and F.A. Troy, NMR studies on how the binding complex of polyisoprenol recognition sequence peptides and polyisoprenols can modulate membrane structure, Curr. Protein Pept. Sci. 6 (2005), pp. 399-411.
68. D.Q. Wei, S. Sirois, Q.S. Du, H.R. Arias, and K.C. Chou, Theoretical studies of Alzheimer's disease drug candidate [(2,4- dimethoxy) benzylidene]-anabaseine dihydrochloride (GTS-21) and its derivatives, Biochem. Biophys. Res. Commun. 338 (2005), pp. 1059-1064. (Pubitemid 41597746)
69. H. Wei, R. Zhang, C. Wang, H. Zheng, K.C. Chou, and D.Q. Wei, Molecular insights of SAH enzyme catalysis and their implication for inhibitor design, J. Theor. Biol. 244 (2007), pp. 692-702. (Pubitemid 46148972)
70. Q.S. Du, S. Wang, D.Q. Wei, S. Sirois, and K.C. Chou, Molecular modelling and chemical modification for finding peptide inhibitor against SARS CoV Mpro, Anal. Biochem. 337 (2005), pp. 262-270. (Pubitemid 40187253)
71. R. Zhang, D.Q. Wei, Q.S. Du, and K.C. Chou, Molecular modeling studies of peptide drug candidates against SARS, Med. Chem. 2 (2006), pp. 309-314. (Pubitemid 44083150)
72. J.F. Wang, D.Q. Wei, and K.C. Chou, Insights from investigating the interactions of adamantane-based drugs with the M2 proton channel from the H1N1 swine virus, Biochem. Biophys. Res. Commun. 388 (2009), pp. 413-417.
73. Q.S. Du, R.B. Huang, S.Q. Wang, and K.C. Chou, Designing inhibitors of M2 proton channel against H1N1 swine influenza virus, PLoS ONE 5 (2010), p. e9388.
74. S.Q. Wang, Q.S. Du, R.B. Huang, D.W. Zhang, and K.C. Chou, Insights from investigating the interaction of oseltamivir (Tamiflu) with neuraminidase of the 2009 H1N1 swine flu virus, Biochem. Biophys. Res. Commun. 386 (2009), pp. 432-436.